of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

CEO — Michael Severino, M.D.: Dr. Michael Severino was appointed as the new CEO of Sarepta Therapeutics, Inc., succeeding Douglas Ingram.

The filing describes the approval of equity incentive and stock purchase plans, not a management change.

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Chief Executive Officer — Douglas Ingram: Douglas Ingram plans to retire as CEO by the end of 2026 or upon the appointment of his replacement.

Results of Operations and Financial Condition. On January 12, 2026, Sarepta Therapeutics Inc. issued a press release disclosing certain business updates, including preliminary financial information as of and for the year and fiscal quarter ended December 31, 2025, in connection with the 44 th Annual J.P. Morgan Healthcare Conference. A copy of the press release is furnished with this report as Exhibit 99.1 and incorporated by reference herein. The information in this report, including Exhibit…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth under

Entry into a Material Definitive Agreement. As previously announced, on December 10, 2025, Sarepta Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 1.25% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”), including the Michael A. Chambers Living Trust, an entity affiliated with Michael Chambers, a member of the Company’s board of directors. Under the terms of the Exchan…

Unregistered Sales of Equity Securities. Exchange Transaction On December 10, 2025, Sarepta Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 1.25% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”), including the Michael A. Chambers Living Trust, an entity affiliated with Michael Chambers, a member of the Company’s board of directors. Under the terms of the Exchange Agre…

CEO — Douglas S. Ingram: The filing discloses the grant of equity compensation to the CEO, which is a compensatory arrangement rather than a change in management or a departure.

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Entry into a Material Definitive Agreement. As previously announced, on August 20, 2025, Sarepta Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 1.25% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”). Under the terms of the Exchange Agreements, the holders party thereto agreed to exchange with the Company $700.0 million in aggregate principal amount of Existing Conver…

Other Events. Concurrently with the issuance of the New Convertible Notes, the Company completed the previously announced private placement of 1,106,806 shares of Common Stock to J. Wood Capital Advisors LLC at a purchase price per share of $18.07, equal to the last reported sale price of our Common Stock on August 27, 2025.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth under

Unregistered Sales of Equity Securities. Exchange Transaction On August 20, 2025, Sarepta Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 1.25% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”). Under the terms of the Exchange Agreements, the holders party thereto have agreed to exchange with the Company approximately $700.0 million in aggregate principal amount of Exi…

EVP, Chief Technical Operations Officer — Bilal Arif: The departure of an Executive Vice President and Chief Technical Operations Officer is a significant management change, but the orderly transition with a consulting agreement and severance suggests a planned restructuring rather than a sudden crisis.

Other Events. On July 21, 2025, the Company announced that the U.S. Food and Drug Administration (“FDA”) has placed a clinical hold on the Company’s investigational gene therapy clinical trials for limb girdle muscular dystrophy (“LGMD”). The hold includes the Company’s LGMD clinical trials related to its product candidates SRP-9003 (LGMD2E/R4/bidridistrogene xeboparvovec), SRP-9004 (LGMD2D/patidistrogene bexoparvovec), SRP-6004 (LGMD2B/R2), and SRP-9005 (LGMD2C/R5 g -sarcoglycan). The Compan…

Results of Operations and Financial Condition. On July 16, 2025, Sarepta Therapeutics, Inc. (the “Company”) issued a press release announcing certain of the Company’s preliminary financial results for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including Exhibit 99.1 attached hereto, is furnished pursuant to

Costs Associated with Exit or Disposal Activities. Following an evaluation of its annual combined research and development and selling, general and administrative spend, the Company is undertaking a restructuring that includes a revised cost structure and program portfolio. In connection with those plans, on July 14, 2025, the Board of Directors of the Company (the “Board”) approved a reduction in force, representing approximately 36% of the Company’s workforce. As a result of this reduction…

CFO — Ryan Wong: The filing discloses the internal promotion of Ryan Wong to CFO and other senior roles, with no indication of a sudden executive departure or termination.

The filing discloses the approval of equity plan amendments (increasing share pools) at the annual meeting, which is a compensatory arrangement matter rather than a change in management or officer roles.

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Entry into a Material Definitive Agreement On February 13, 2025 (the “Closing Date”), Sarepta Therapeutics, Inc. (the “Company”) and Sarepta Therapeutics Investments, Inc., a wholly owned subsidiary of the Company (together with the Company, the “Obligors”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”) and as collateral agent (in such capacity, the “Collateral Agent”) and the lend…